Jazz Pharmaceuticals plc (NASDAQ:JAZZ) CAO Patricia Carr Sells 4,813 Shares

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) CAO Patricia Carr sold 4,813 shares of the company’s stock in a transaction dated Thursday, February 27th. The shares were sold at an average price of $144.42, for a total transaction of $695,093.46. Following the sale, the chief accounting officer now directly owns 8,237 shares of the company’s stock, valued at approximately $1,189,587.54. This represents a 36.88 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this hyperlink.

Jazz Pharmaceuticals Stock Performance

NASDAQ:JAZZ opened at $140.22 on Tuesday. The stock has a market capitalization of $8.52 billion, a P/E ratio of 19.75, a PEG ratio of 1.04 and a beta of 0.56. The company has a debt-to-equity ratio of 1.46, a quick ratio of 3.74 and a current ratio of 4.26. Jazz Pharmaceuticals plc has a fifty-two week low of $99.06 and a fifty-two week high of $148.06. The company has a 50 day moving average price of $127.01 and a 200 day moving average price of $119.37.

Analyst Upgrades and Downgrades

JAZZ has been the topic of several recent research reports. HC Wainwright restated a “buy” rating and set a $200.00 target price on shares of Jazz Pharmaceuticals in a report on Friday, November 22nd. Needham & Company LLC boosted their price objective on Jazz Pharmaceuticals from $205.00 to $210.00 and gave the stock a “buy” rating in a research note on Wednesday, February 26th. Morgan Stanley raised Jazz Pharmaceuticals from an “equal weight” rating to an “overweight” rating and raised their target price for the stock from $140.00 to $175.00 in a research note on Thursday, December 12th. Cantor Fitzgerald lowered Jazz Pharmaceuticals from an “overweight” rating to a “neutral” rating and lifted their price target for the stock from $140.00 to $150.00 in a report on Wednesday, February 26th. Finally, JPMorgan Chase & Co. upped their price objective on shares of Jazz Pharmaceuticals from $200.00 to $209.00 and gave the company an “overweight” rating in a report on Wednesday, February 26th. Two equities research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, Jazz Pharmaceuticals has an average rating of “Moderate Buy” and an average price target of $182.47.

Institutional Investors Weigh In On Jazz Pharmaceuticals

A number of institutional investors have recently modified their holdings of the company. Fuller & Thaler Asset Management Inc. lifted its stake in Jazz Pharmaceuticals by 117.4% during the 4th quarter. Fuller & Thaler Asset Management Inc. now owns 939,351 shares of the specialty pharmaceutical company’s stock worth $115,681,000 after acquiring an additional 507,234 shares in the last quarter. Darwin Global Management Ltd. acquired a new position in Jazz Pharmaceuticals in the 4th quarter valued at about $59,668,000. Dimensional Fund Advisors LP increased its stake in Jazz Pharmaceuticals by 18.7% during the fourth quarter. Dimensional Fund Advisors LP now owns 2,035,070 shares of the specialty pharmaceutical company’s stock worth $250,619,000 after purchasing an additional 320,724 shares during the period. Ameriprise Financial Inc. lifted its position in shares of Jazz Pharmaceuticals by 20.9% during the fourth quarter. Ameriprise Financial Inc. now owns 1,827,658 shares of the specialty pharmaceutical company’s stock worth $225,076,000 after purchasing an additional 315,608 shares in the last quarter. Finally, GMT Capital Corp boosted its stake in shares of Jazz Pharmaceuticals by 140.0% in the fourth quarter. GMT Capital Corp now owns 508,800 shares of the specialty pharmaceutical company’s stock valued at $62,659,000 after purchasing an additional 296,800 shares during the period. 89.14% of the stock is owned by institutional investors and hedge funds.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.